Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study

BACKGROUND: Calcitonin gene‐related peptide (CGRP) inhibitors were introduced in the United States (US) in 2018. To understand the changing patterns of preventive treatment following the introduction of these new agents, we must first characterize the patterns which preceded their introduction. OBJE...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawata, Ariane K., Shah, Neel, Poon, Jiat‐Ling, Shaffer, Shannon, Sapra, Sandhya, Wilcox, Teresa K., Shah, Shweta, Tepper, Stewart J., Dodick, David W., Lipton, Richard B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048891/
https://www.ncbi.nlm.nih.gov/pubmed/33594686
http://dx.doi.org/10.1111/head.14053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048891/
https://www.ncbi.nlm.nih.gov/pubmed/33594686
http://dx.doi.org/10.1111/head.14053

Ejemplares similares